Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Dopamine receptor antagonists like metoclopramide and domperidone block D2 receptors in the GI tract, neutralizing dopamine's inhibitory effects on motility. This blockade increases lower esophageal sphincter pressure and promotes coordinated GI contractions, enhancing food movement through the digestive system and improving overall gastrointestinal function.

Dopamine is an inhibitory neurotransmitter abundant in the GI tract that binds to D2 receptors, lowering intragastric pressures and relaxing the lower esophageal sphincter. By inhibiting GI motility, dopamine slows food transit through the digestive system. Understanding dopamine's role is essential for comprehending how enteric nervous system regulation of GI motor activity controls digestion.

Metoclopramide treats gastroparesis by enhancing gastric emptying and manages gastroesophageal reflux disease and nausea or vomiting. It also serves as an adjuvant for GI diagnostic procedures like endoscopy. The drug works by blocking dopamine receptors and increasing acetylcholine release, both promoting GI motility and reducing nausea through chemoreceptor trigger zone inhibition.

Metoclopramide crosses the blood-brain barrier, causing central nervous system side effects including insomnia, anxiety, tremors, dystonia, and dyskinesia. Domperidone has fewer central nervous system effects but may increase cardiac arrhythmia risk. Both drugs can elevate prolactin levels, causing galactorrhea or gynecomastia. Domperidone is available through FDA expanded access for investigational drugs.

Metoclopramide is absorbed quickly, acting within 1-2 hours of oral intake with a half-life of 4-6 hours. The drug undergoes hepatic sulfation and glucuronide conjugation before urinary excretion. This rapid onset and moderate duration make it suitable for acute GI symptoms and diagnostic procedures requiring prompt GI tract preparation.

Beyond blocking D2 receptors in the GI tract, dopamine receptor antagonists like metoclopramide and domperidone also block D2 receptors in the brain's chemoreceptor trigger zone. This central action mitigates nausea and vomiting signals, providing antiemetic effects independent of their prokinetic properties and making them effective for multiple GI-related symptoms.

Domperidone is metabolized by hepatic CYP3A4 enzyme through N-dealkylation and hydroxylation pathways. Unlike metoclopramide, which undergoes sulfation and glucuronide conjugation, domperidone's CYP3A4-dependent metabolism may increase drug interaction potential. This metabolic difference contributes to domperidone's distinct pharmacokinetic profile and clinical considerations.